Transient central precocious puberty: a new entity among the spectrum of precocious puberty?

Ital J Pediatr. 2021 Oct 23;47(1):210. doi: 10.1186/s13052-021-01163-9.

Abstract

Objective: Recently, we observed some cases of Precocious Puberty (PP) with a partial central activation of hypothalamic-pituitary-gonadal (HPG) axis that tended to normalized in 6-12 months. To evaluate the frequency of this form within the spectrum of forms of PP, we retrospectively assessed the clinical, hormonal and ultrasound characteristics of patients attending to our Center for signs of PP, between 2007 and 2017. To hypothesize some causes of this "pubertal poussée" a questionnaire about environmental data was provided to patients.

Methods: 96 girls were recruited for the study and divided into three Groups. Group 1: 56 subjects with Central PP (CPP) requiring treatment with GnRH analogue; Group 2: 22 subjects with transient activation of pubertal axis, that tended to normalize, "Transient CPP"(T-CPP); Group 3: 18 subjects with Isolated Thelarche (IT).

Results: Mean age at diagnosis was 6.8 ± 1.0 years in Group 1, 5.9 ± 1.3 years in Group 2 and 5.6 ± 1.5 years in Group 3. A significant increase of diagnosis of T-CPP was observed over the study period. Significantly higher use of some homeopathic medicines and potential exposure to pesticides was reported in Group 2 vs Group 1.

Conclusions: To our knowledge, we first reported a form defined as T-CPP, characterized by partial activation in the HPG axis normalizing over time. An increased use of homeopathic medicines and exposure to environmental pollutants in these patients was evidenced.

Keywords: Central precocious puberty; Endocrine disruptors; Herbicides and pesticides; Nutritional factors; Thelarche; Transient precocious puberty.

MeSH terms

  • Child
  • Estradiol / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Gonadotropin-Releasing Hormone / analogs & derivatives
  • Humans
  • Luteinizing Hormone / blood
  • Puberty, Precocious / diagnosis*
  • Retrospective Studies
  • Triptorelin Pamoate / administration & dosage
  • Ultrasonography
  • Uterus / diagnostic imaging

Substances

  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone